# Junta clínica — PT-pseudo_3b6ea1920967 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_3b6ea1920967",
  "pid": "PT-pseudo_3b6ea1920967",
  "task": 1,
  "psa": 6.5,
  "age": 64,
  "months": 3,
  "pirads": "4",
  "psad": 0.11,
  "psav": 1.22,
  "psap": 4.5,
  "vol": 59.14,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.7465537,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 6.5 ng/mL. PI-RADS 4. PSAD 0.11. Prostate volume 59 mL. csPCa 0.75.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "70 kg",
    "height": "174 cm",
    "bmi": "23.1",
    "bp": "146/61 mmHg",
    "hr": "63 bpm",
    "smoking": "Ex-smoker (38 pack-yr, quit 2007)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "11 Jan 2025",
  "enc_ref": "Dr. K. Bakker (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical assessment required due to a prior prostate cancer diagnosis coupled with a recent PSA increase to 6.5 ng/mL."
    },
    {
      "s": "History",
      "t": "A 64-year-old retired primary school teacher initially came to medical attention for an incidental PSA rise in early 2023 and has since remained under surveillance after his first positive biopsy. He is widowed and shares his home with a long-term partner, enjoying an active routine that features weekend hiking alongside moderate alcohol intake of roughly four units weekly. He reports moderate lower urinary tract symptoms scoring 13 on the IPSS, while explicitly denying hematuria, bone pain, or unexplained weight loss. His smoking history includes 38 pack-years, having ceased consumption in 2007. He maintains a residence situated over ninety minutes from the clinic and has expressed a preference for telephone follow-ups when clinically suitable, having recently finished a baseline memory clinic screening and a standard audiology assessment."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland presents as symmetrically enlarged without palpable nodules. General examination remains unremarkable, with stable vital signs, clear lung fields, and a regular cardiac rhythm. Peripheral lymphadenopathy and abdominal masses are notably absent."
    }
  ],
  "occupation": "retired primary school teacher",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Audiology — hearing test",
    "Memory clinic — baseline screening"
  ],
  "alcohol": "4 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 13/35 (moderate LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Erasmus MC",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3b6ea1920967
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 64-year-old male
  - PSA: 6.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.11 ng/mL²
  - PSA velocity: 1.22 ng/mL/yr
  - Prior PSA: 4.5 ng/mL
  - Prostate volume: 59.14 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7465537 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 6.5 ng/mL. PI-RADS 4. PSAD 0.11. Prostate volume 59 mL. csPCa 0.75.

Vitals: weight 70 kg, height 174 cm, BMI 23.1, BP 146/61 mmHg, HR 63 bpm. Smoking: Ex-smoker (38 pack-yr, quit 2007).

Chief complaint: Clinical assessment required due to a prior prostate cancer diagnosis coupled with a recent PSA increase to 6.5 ng/mL.

History: A 64-year-old retired primary school teacher initially came to medical attention for an incidental PSA rise in early 2023 and has since remained under surveillance after his first positive biopsy. He is widowed and shares his home with a long-term partner, enjoying an active routine that features weekend hiking alongside moderate alcohol intake of roughly four units weekly. He reports moderate lower urinary tract symptoms scoring 13 on the IPSS, while explicitly denying hematuria, bone pain, or unexplained weight loss. His smoking history includes 38 pack-years, having ceased consumption in 2007. He maintains a residence situated over ninety minutes from the clinic and has expressed a preference for telephone follow-ups when clinically suitable, having recently finished a baseline memory clinic screening and a standard audiology assessment.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland presents as symmetrically enlarged without palpable nodules. General examination remains unremarkable, with stable vital signs, clear lung fields, and a regular cardiac rhythm. Peripheral lymphadenopathy and abdominal masses are notably absent.

Patient info: retired primary school teacher; Widowed; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Hiking on weekends; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Memory clinic — baseline screening.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.59
  uncertainty  +/- 0.12 epistemic (95% band 0.36-0.83); among patients I cannot tell apart the outcome was 0.98 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.36: PI-RADS 4, PSA 5.3, PSAD 0.092, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 65 years old patient"
  2. distance 0.89: PI-RADS 4, PSA 6.8, PSAD 0.2, age 62, DRE Normal -> DEFER (borderline). He wrote: "All depends if the lesion has grown in size since 2024. If stable no biopsy , if increased in size I will do a biopsy."
  3. distance 0.93: PI-RADS 4, PSA 6.7, PSAD 0.2, age 67, DRE Normal -> BIOPSY (borderline). He wrote: "Active surveillance, only one previous biopsy 2 yrs ago. Stable findings (stable PIRADS4, slightly increasing PSA) -> borderline indication for biopsy. As only one previ…"

PRECEDENT: BIOPSY (weighted vote 0.77 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline emphasizes that the decision hinges on the MRI findings and the histological progression, which are not fully detailed in the panel. The precedent cited by Expert 5 shows that the decision was borderline, suggesting that the specific details of the prior biopsy grade and surveillance history are critical variables that the guideline does not override.

WHAT WE STILL NEED
The guideline requires information on the grade of the prior biopsy and the number and dates of biopsy sessions in the notes to determine the next step.
Prior biopsy status is documented as "Positive" on the panel, and the specific Gleason or ISUP grade and biopsy dates are not provided in the minute.
The number of biopsy sessions and dates is not documented, which is required to assess surveillance history.
The patient's PSA value of 6.5 ng/mL is above the threshold of 20 ng/mL mentioned in one guideline, but the guideline does not provide a definitive action for this specific value in this context.
The MRI prose is not available to assess if it compares against an earlier study, which is required by the trace model.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the specific grade and history of the prior biopsy to determine the appropriate surveillance pathway.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the MRI prose indicate if the lesion has grown in size since an earlier study?
  psa_trend (get_psa_trend) -> Does the PSA trend provide information on the rate of change beyond the headline value?
  previous_notes (get_previous_notes) -> What is the Gleason or ISUP grade of the prior biopsy, and what is the surveillance history?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the Gleason or ISUP grade of the prior biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The MRI prose indicates the presence of a focal hypointense abnormality in the left mid peripheral zone, spanning roughly 11 mm. It does not explicitly state if the lesion has grown in size since an earlier study.

psa_trend
The PSA trend shows values: {"date": "Jan 2023", "val": 2.1}, {"date": "Sep 2023", "val": 3.1}, {"date": "May 2024", "val": 4.5}, {"date": "Jan 2025", "val": 6.5}. This provides information on the rate of change beyond the headline value.

previous_notes
The Gleason or ISUP grade of the prior biopsy is not recorded. The surveillance history is that a follow-up PSA was requested after a PSA escalation from 4.5 ng/mL to 5.1 ng/mL, which triggered the current referral.

WHAT I DID NOT OPEN
I did not open the laboratory_results or the family-history anamnesis because the required information regarding the prior biopsy grade and surveillance history was found in the previous_notes.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
The PSA trend shows a clear upward trajectory, culminating in a 6.5 ng/mL value.
The MRI report identifies a PI-RADS 4 lesion, which is a high-risk finding.

Findings that argue AGAINST sampling this patient now:
The previous notes do not document the Gleason or ISUP grade of the prior biopsy.
The previous notes do not document the number and dates of prior biopsy sessions or surveillance protocol status.

WHERE THIS LEANS
The available information strongly points toward needing the specific details from the previous notes to determine the next step, which is currently missing.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.50 ng/mL over 4 points spanning 24 months; velocity +2.19 ng/mL per year; doubling time about 15 months.
PROJECTION at 6 months: 9.4 ng/mL, conformal 95% band 2.7-32.6.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.65
  uncertainty  +/- 0.10 epistemic (95% band 0.45-0.85), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.59  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.65  ('supports' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.77  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.65 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_nolab). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—were retrieved. The registrar reported that the Gleason or ISUP grade of the prior biopsy is not recorded, and the surveillance history is incomplete.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a BIOPSY based on a weighted vote, despite the lack of documented prior grade. The retrieved information confirms the uncertainty noted by Expert 1 and Expert 3, as the critical variables (prior grade and surveillance history) were not present in the retrieved documents.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the Gleason or ISUP grade of the prior biopsy? This question remains unanswered as the previous_notes explicitly state the grade is not recorded.
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? This question remains unanswered as the previous_notes do not document the number or dates of sessions or surveillance status.

WHAT CARRIES WEIGHT, AND WHY
The PSA trend, showing a clear upward trajectory to 6.5 ng/mL, and the PI-RADS 4 finding in the MRI are important because they indicate high-risk disease behavior. However, the lack of documented prior biopsy grade and surveillance history is critical because the EAU guideline and the panel protocol explicitly state these details are required to determine the next step.

MY SUGGESTION TO THE CHAIR
Given that the required information to definitively guide the next step is missing from the retrieved documents, the decision cannot be made yet according to the guideline's requirements.

VERDICT: not-ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

A biopsy is recommended because the PSA trend shows a clear upward trajectory to 6.5 ng/mL, and the MRI identified a high-risk PI-RADS 4 lesion. Although the specific prior biopsy grade and surveillance history were not documented, the combination of high-risk imaging and rising PSA behavior supports proceeding with further tissue sampling to clarify the situation. The evidence converged on the need for further investigation.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
